ReviewMolecular imaging and biology2014
Targeted radionuclide and fluorescence dual-modality imaging of cancer: preclinical advances and clinical translation.
Review in Molecular imaging and biology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.
- Current and future intraoperative imaging strategies to increase radical resection rates in pancreatic cancer surgery.BioMed research international · 2014Pooled it
- Dual-Modality SPECT and Viscosity-Responsive AIE Fluorescence Probe for Pancreatic Cancer Diagnosis and Intraoperative Guidance.ACS omega · 2026Article
- Bimodal Fluorescent Conjugate Based on Prostate-Specific Membrane Antigen Ligands with the Chelating Agent DOTA and SulfoCy5 Dye: Synthesis, Radiolabeling, and Biological Activity.International journal of molecular sciences · 2026Article
- Cancer-Associated Fibroblasts: Heterogeneity, Cancer Pathogenesis, and Therapeutic Targets.MedComm · 2025Review
- Preclinical evaluation of zirconium-89 labeled anti-Trop2 antibody-drug conjugate (Trodelvy) for imaging in gastric cancer and triple-negative breast cancer.European journal of nuclear medicine and molecular imaging · 2025Article
- eTFC-01: a dual-labeled chelate-bridged tracer for SSTR2-positive tumors.EJNMMI radiopharmacy and chemistry · 2024Article
- Emerging Multifunctional Carbon-Nanomaterial-Based Biosensors for Cancer Diagnosis.Small science · 2024Article
- Emergence and impact of theranostic-nanoformulation of triple therapeutics for combination cancer therapy.Smart medicine · 2024Review
- Dual probe difference specimen imaging for prostate cancer margin assessment.Journal of biomedical optics · 2023Article
- Asymmetric rotaxanes as dual-modality supramolecular imaging agents for targeting cancer biomarkers.Communications chemistry · 2023Article
- Strain-Promoted Azide-Alkyne Cycloaddition-Based PSMA-Targeting Ligands for Multimodal Intraoperative Tumor Detection of Prostate Cancer.Bioconjugate chemistry · 2022Article
- Non-invasive in vivo imaging of acute thrombosis: development of a novel factor XIIIa radiotracer.European heart journal. Cardiovascular Imaging · 2020Article
- Hybrid Imaging Agents for Pretargeting Applications Based on Fusarinine C-Proof of Concept.Molecules (Basel, Switzerland) · 2020Article
- Targeted Nanobubbles Carrying Indocyanine Green for Ultrasound, Photoacoustic and Fluorescence Imaging of Prostate Cancer.International journal of nanomedicine · 2020Article
- Characterization and validation of multimodal annihilation-gamma/near-infrared/visible laparoscopic system.Journal of biomedical optics · 2019Article
- New Developments in Dual-Labeled Molecular Imaging Agents.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2019Review
- Article
- Synthesis and Preclinical Characterization of the PSMA-Targeted Hybrid Tracer PSMA-I&F for Nuclear and Fluorescence Imaging of Prostate Cancer.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2019Article
- Emerging Fluorescent Molecular Tracers to Guide Intra-Operative Surgical Decision-Making.Frontiers in pharmacology · 2019Review
- PSMA-targeting agents for radio- and fluorescence-guided prostate cancer surgery.Theranostics · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In oncology, sensitive and reliable detection tumor tissue is crucial to prevent recurrences and to improve surgical outcome. Currently, extensive research is focused on the use of radionuclides as well as fluorophores to provide real-time guidance during surgery to aid the surgeon in the identification of malignant tissue. Particularly, dual-modality approaches combining radionuclide and near-infrared fluorescence (NIRF) imaging have shown promising results in preclinical studies. Radionuclide imaging allows sensitive intra-operative localization of tumor lesions using a gamma probe, whereas NIRF imaging allows more accurate real-time tumor delineation. Consequently, both radionuclide and NIRF imaging might complement each other, and dual-modality image-guided surgery may overcome limitations of the currently used single-modality imaging techniques. In this review, a comprehensive overview on recent preclinical advances in tumor-targeted radionuclide and fluorescence dual-modality imaging is provided. Subsequently, the clinical applicability of dual-modality image-guided surgery is discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.